论文部分内容阅读
目的观察瑞格列奈与格列齐特对2型糖尿病(Type 2 diabetes mellitus,T2DM)患者血糖及胰岛β细胞分泌功能的影响。方法选取2015年7月—2017年4月收治的102例T2DM患者作为研究对象,运用随机数表法将入选者分为两组,各51例。对照组给予格列齐特治疗,观察组给予瑞格列奈治疗。观察两组治疗前后血糖与胰岛β细胞分泌功能的变化,评价两组用药安全性。计量资料比较采用t检验,P<0.05为差异有统计学意义。结果治疗前两组空腹血糖(Fasting blood glucose,FBG)、餐后2 h血糖(2-hour Postprandial Blood Glucose,2h PBG)、胰岛素早相分泌指数(IRG)、胰岛素曲线下面积(AUCi)/葡萄糖曲线下面积(AUCg)水平比较,差异无统计学意义(均P>0.05);治疗后观察组2h PG低于对照组,IRG、AUCi/AUCg高于对照组,差异有统计学意义(均P<0.05);两组均未出现严重不良反应。结论瑞格列奈治疗T2DM安全高效,有效降低餐后血糖水平,提升胰岛β细胞分泌功能。
Objective To observe the effect of repaglinide and gliclazide on the blood glucose and pancreatic β-cell secretion in type 2 diabetes mellitus (T2DM) patients. Methods A total of 102 patients with T2DM admitted from July 2015 to April 2017 were selected as study subjects. The random number table method was used to divide the patients into two groups (n = 51). The control group was given gliclazide and the observation group was given repaglinide. The changes of blood glucose and pancreatic β-cell secretion before and after treatment were observed to evaluate the safety of the two groups. Measurement data were compared using t test, P <0.05 for the difference was statistically significant. Results Before treatment, fasting blood glucose (FBG), 2-hour postprandial blood glucose (2h PBG), insulin secretion index (IRG), area under the curve of insulin (AUCi) / glucose (P> 0.05). After treatment, 2 h PG in the observation group was lower than that in the control group, IRG and AUCi / AUCg were higher than those in the control group (P <0.05) <0.05). No serious adverse reactions occurred in both groups. Conclusion Repaglinide is safe and effective in treating T2DM, effectively reducing postprandial blood glucose levels and enhancing pancreatic β-cell secretion.